Covestro AG Overview
Covestro is one of the world's largest producers of high-performance polymer materials and their precursors, built on Bayer's eight-decade legacy in polyurethane and polycarbonate chemistry. It sits in the upstream-to-midstream portion of the chemical value chain, converting petrochemical (and increasingly bio-based and recycled) feedstocks into isocyanates (MDI, TDI, HDI and aliphatic derivatives), polyols, polycarbonate resins and specialty systems for coatings, adhesives, elastomers and films. Roughly half of revenue comes from scale-driven commodity-like "Performance Materials" and half from customer-specific "Solutions & Specialties". After three years of cyclical trough (sales down from €18.0bn in 2022 to €12.9bn in 2025 and net losses each year), Covestro was acquired by ADNOC's international chemicals vehicle XRG in a ~€14.7bn transaction completed in late 2025, giving it a deep-pocketed, feedstock-integrated strategic owner. Its strategic thesis is "Sustainable Future": leadership in circular, climate-neutral polymers, now combined with Gulf-based capacity growth.
What the company does
Covestro manufactures polymer materials and components. Its chemistry falls into three technology families:
-
Polyurethanes (PU) — isocyanates (MDI for rigid foams, TDI for flexible foams) and polyether polyols, sold to foam makers for insulation (construction, refrigeration/cold chain) and comfort (furniture, mattresses, automotive seating).
-
Polycarbonates (PC) — engineering thermoplastic (Makrolon® brand) and compounds/blends (Bayblend®, Makroblend®) for automotive, electrical & electronics, healthcare, lighting and construction glazing.
-
Coatings, Adhesives & Specialties — aliphatic isocyanates and derivatives (HDI, IPDI, H12MDI; Desmodur®), polyols/resins (Desmophen®, Bayhydrol®), the former DSM Resins & Functional Materials portfolio (NeoCryl®, NeoRez®, Decovery®), thermoplastic polyurethanes (Desmopan®), elastomers, and specialty films (Makrofol®, Platilon®).
Business model and revenue model
Product sales ≈ ~100% of revenue: Covestro does not report material service, subscription or licensing revenue; technology licensing and engineering services are incidental (n/d as a separate line).
Performance Materials: behaves as a cost-leadership, scale business with prices set by global supply/demand for MDI/TDI/polyols/PC; margins swing sharply with industry utilisation and raw material (benzene, toluene, propylene, chlorine, natural gas, energy) spreads.
Solutions & Specialties: is a formulation- and application-driven business: tailored grades, technical service, co-development with OEMs, stickier pricing and higher, more stable margins.
Value-chain position
Upstream: buys aromatics (benzene, toluene), propylene, natural gas/energy, chlorine (partly produced in-house via chlor-alkali electrolysis), phenol/acetone/bisphenol A inputs. Midstream: isocyanate, polyol and PC production at large integrated "world-scale" sites (Leverkusen, Dormagen, Krefeld-Uerdingen, Antwerp, Baytown, Shanghai, Tarragona, Map Ta Phut). Downstream: sells mostly B2B to converters (foam producers, compounders, coaters, adhesive formulators) and OEMs.
Customer types and end-markets
Covestro's largest end-markets (historically disclosed shares; latest split n/v) are construction (insulation, floor coatings), automotive & transportation (seating, interiors, lighting, coatings, e-mobility battery housings), furniture & wood processing (mattresses, wood coatings), electrical & electronics (housings, displays), sports & leisure, cosmetics, healthcare (medical-grade PC and TPU), and chemicals/industrial.
Company self-description (latest annual reporting, paraphrased)
Covestro describes itself as one of the world's leading manufacturers of high-quality polymer materials and their components, pursuing a vision of becoming fully circular and supporting customers' sustainability goals ("Sustainable Future" strategy). Every investor release in 2026 closes with: sales €12.9bn in FY2025, 46 production sites, ~17,600 FTE.
Independent characterisation
Covestro is fundamentally a cyclical isocyanates/polycarbonate producer with a growing specialty overlay. Its earnings power is dominated by MDI and PC margins, which collapsed in 2022–2025 due to Chinese capacity additions (notably Wanhua), weak European construction, high German energy costs and soft durable-goods demand. Its strategic differentiators are (a) technology leadership and process efficiency in MDI/TDI/PC, (b) one of the broadest aliphatic isocyanate franchises globally (coatings & adhesives), and (c) an early-mover position in circular feedstocks (chemical recycling of PU foam and PC, bio-attributed MDI/PC). Under XRG ownership, the investment case shifts from public-market equity story to an integrated Gulf-feedstock growth platform, evidenced by the July 2026 MDI expansion program in China and the UAE.
Strategy
Corporate strategy — "Sustainable Future" (launched 2023): become fully circular; focus on growth in sustainable solutions; climate-neutral operations (Scope 1 & 2) by 2035; Scope 3 by 2050 (targets n/v in detail).
Key initiatives (last 24 months)
Guidance (FY2026, as of 9 July 2026 / H1 report)
Medium-term targets as a listed company are no longer published.
Products & Services
Performance Materials
| Product line | Description / capabilities | Target customers | Flagship / notes |
|---|---|---|---|
| MDI (methylene diphenyl diisocyanate) | Isocyanate for rigid PU foam, binders, elastomers | Insulation panel makers, appliance (refrigeration) OEMs, construction | Desmodur® 44 series; world-scale plants Brunsbüttel, Krefeld-Uerdingen, Tarragona, Baytown, Shanghai; ~660 kt expansion program (China/UAE) announced July 2026 |
| TDI (toluene diisocyanate) | Isocyanate for flexible slabstock and molded foam | Mattress, furniture, automotive seat makers | Gas-phase phosgenation technology (Dormagen, Shanghai) |
| Polyether polyols | Reactive partner for isocyanates | Foam producers | Arcol®/Desmophen® grades; Dormagen polyols affected by Rhine low-water force majeure (2026) |
| Standard polycarbonate resin | Transparent, impact-resistant thermoplastic | Compounders, sheet/film producers, E&E, automotive | Makrolon® base grades |
| CO2-based / bio-attributed materials | Polyols made partly from CO2 (cardyon®); mass-balance bio-circular MDI/PC (ISCC PLUS) | Brands with Scope 3 targets | cardyon® launched 2016; "CQ" product label for circular-attributed products |
| Chlorine & co-products | Chlor-alkali for captive phosgene/isocyanate chain | Internal use; some external sales | Oxygen-depolarised cathode technology |
Solutions & Specialties
| Product line | Description / capabilities | Target customers | Flagship / notes |
|---|---|---|---|
| Aliphatic isocyanates (HDI, IPDI, H12MDI, PDI) | Light-stable crosslinkers for high-performance PU coatings | Automotive OEM/refinish, industrial, marine, wood coatings formulators | Desmodur® N; Desmodur® eco N (partly bio-based PDI); capacity extended by Vencorex Rayong & Freeport sites (July 2026) |
| Coating polyols & dispersions | Waterborne and solvent-borne resins | Coatings formulators | Desmophen®, Bayhydrol®, Bayhydur® |
| Former DSM RFM resins | Waterborne acrylics, urethane dispersions, powder coating resins, bio-based resins, functional materials (optical fibre coatings, additive manufacturing resins) | Decorative and industrial coatings, graphic arts | NeoCryl®, NeoRez®, Decovery®, Uralac® (powder), Niaga® (circular design) — acquired April 2021 |
| Adhesives raw materials | Polyurethane dispersions and prepolymers | Footwear, automotive interior, packaging adhesives | Dispercoll® U |
| Engineering plastics (PC compounds and blends) | PC/ABS, PC/PBT, flame-retardant and medical grades | Automotive lighting/interiors, E&E housings, EV battery components, healthcare | Bayblend®, Makroblend®, Makrolon® specialty and Rx medical grades; Apec® high-heat PC |
| Thermoplastic polyurethane (TPU) | Elastomeric, abrasion-resistant | Footwear, sports, cables, 3D printing | Desmopan®, Texin® |
| Elastomers & tailored urethanes | Cast elastomers, PU systems | Industrial rollers, mining, automotive | Baytec®, Vulkollan® |
| Specialty films | PC and TPU films for ID cards, displays, medical, electronics | Security documents, electronics | Makrofol®, Platilon® |
| Systems houses | Formulated PU systems for insulation, CASE | Regional converters | Regional system houses (network size n/v) |
Pricing models are not disclosed; sales are predominantly contract and spot pricing linked to market indices for PM, and negotiated, value-based pricing for S&S. Product launch years beyond those noted are n/v.
Financial Narrative
Income statement
Sources: Covestro Annual Reports 2021–2025 and FY press releases. FY2024 and FY2025 figures verified against AR 2025 ("Results of Operations, Financial Position and Net Assets"). Revenue CAGR FY2021–FY2025: –5.0% p.a. (derived).
Commentary. Covestro's P&L shows a classic commodity-chemical down-cycle. 2021 marked a cyclical peak (EBITDA margin ~19%), driven by post-COVID restocking and tight MDI/PC markets. In 2022 record sales were price-inflated (energy/raw-material pass-through), but margins collapsed and impairments pushed net income negative. 2023–2025 saw both price deflation (sales –28% from 2022 to 2025) and margin compression. FY2025 was the trough: EBITDA –30.9% to €740m, EBIT –€347m and net loss –€644m, driven by lower selling prices across all regions, FX headwinds, the Dormagen fire, and higher D&A/impairments (€1,087m). Management had initially guided €1.0–1.6bn EBITDA for 2025 and cut to €700–800m on 30 Oct 2025.
Quarterly bridge FY2025
Q2 and Q3 sales rounded as released (€3.4bn; €3.2bn); Q1 sales derived as residual and therefore approximate. Q1 EBITDA derived from H1 2025 EBITDA (€407m) less Q2 (€270m). Note: quarterly net income sums to –€678m vs. FY –€644m reported — the €34m discrepancy likely reflects rounding/restatement or attribution differences and is flagged unresolved.
H1 2026 performance (Half-Year Financial Report 2026)
H1 2025 sales derived from quarterly figures above (approximate). EBITDA rose 64.4% on higher selling prices with raw-material costs lagging; FX was a headwind. Net income turned positive (€120m).
Balance sheet and cash flow
Dividends paid: €0 for FY2022–FY2025 (dividend suspended); buybacks: none since the €1.5bn programme of 2022 was halted (n/v detail).
Commentary. The €1.17bn capital increase subscribed by XRG at closing is the dominant driver of the 31% fall in net financial debt to €1,796m despite negative free operating cash flow. The large FY2025 investing outflow (€1.3bn) likely reflects placement of capital-increase proceeds into short-term financial investments (breakdown n/v). Capex was held flat at ~€0.8bn — high relative to depressed EBITDA (capex/EBITDA >100% in FY2025).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Principal products |
|---|---|---|
Performance Materials (PM) | Standardised, high-volume materials | MDI, TDI, polyether polyols, standard polycarbonate resins, chlorine/precursors |
Solutions & Specialties (S&S) | Customised, application-intensive materials | Coatings & adhesives raw materials (aliphatic isocyanates, resins, DSM RFM portfolio), engineering plastics (PC compounds/blends), tailored urethanes (TPU, elastomers, systems), specialty films |
All other / reconciliation | Corporate functions, intersegment eliminations, other businesses | — |
Revenue by Segment
| Segment | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Performance Materials sales (EUR Mn) | n/v | 6,940 | 6,100 |
Solutions & Specialties sales (EUR Mn) | 7,300 | 7,000 | 6,600 |
Group sales (EUR Mn) | 14,377 | 14,179 | 12,942 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Segment | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Solutions & Specialties EBITDA (EUR Mn) | 817 | 740 | 681 |
Performance Materials EBITDA (EUR Mn)
| Performance Materials EBITDA (EUR Mn) | n/v | n/v | n/v |
|---|---|---|---|
Group EBITDA (EUR Mn) | 1,080 | 1,071 | 740 |
Results by Segment (Half-Yearly)
| Segment | H1 2025 | H1 2026 |
|---|---|---|
Performance Materials EBITDA (EUR Mn) | 162 | 334 |
Solutions & Specialties EBITDA (EUR Mn) | 356 | 465 |
All other segments EBITDA (EUR Mn) | 24 | 11 |
Reconciliation EBITDA (EUR Mn) | -135 | -141 |
Group EBITDA (EUR Mn) | 407 | 669 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Sales (EUR Mn) | 15,903 | 17,968 | 14,377 | 14,179 | 12,942 |
EBITDA (EUR Mn) | 3,070 | 1,617 | 1,080 | 1,071 | 740 |
Depreciation amortisation and impairments (EUR Mn) | n/v | n/v | n/v | 984 | 1,087 |
EBIT (EUR Mn) | n/v | n/v | n/v | 87 | -347 |
Financial result (EUR Mn) | n/v | n/v | n/v | -114 | -145 |
Net income (EUR Mn) | 1,616 | -272 | -198 | -266 | -644 |
EPS basic (EUR) | 8.37 | -1.42 | -1.05 | n/v | n/v |
Dividend per share (EUR) | 3.40 | 0 | 0 | 0 | 0 |
EBITDA margin (%) | 19.3 | 9.0 | 7.5 | 7.6 | 5.7 |
Net margin (%) | 10.2 | -1.5 | -1.4 | -1.9 | -5.0 |
Income Statement
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|
Sales (EUR Mn) | 3,427 | 3,400 | 3,200 | 2,915 |
EBITDA (EUR Mn) | 137 | 270 | 242 | 91 |
Net income (EUR Mn) | -160 | -59 | -47 | -412 |
Free operating cash flow (EUR Mn) | -253 | -228 | 111 | 87 |
Income Statement (Half-Yearly)
| Metric | H1 2025 | H1 2026 |
|---|---|---|
Sales (EUR Mn) | 6,827 | 6,729 |
EBITDA (EUR Mn) | 407 | 669 |
EBIT (EUR Mn) | -48 | 244 |
Net income attributable (EUR Mn) | -219 | 120 |
Cash Flow and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (EUR Mn) | n/v | n/v | n/v | 870 | 487 |
Capex PPE and intangibles (EUR Mn) | n/v | n/v | n/v | 781 | 770 |
Free operating cash flow (EUR Mn) | 1,463 | 377 | 232 | 89 | -283 |
Net investing cash flow (EUR Mn) | n/v | n/v | n/v | -423 | -1,295 |
Net financing cash flow (EUR Mn) | n/v | n/v | n/v | -565 | 968 |
Net financial debt (EUR Mn) | n/v | n/v | n/v | 2,618 | 1,796 |
ROCE (%) | n/v | n/v | n/v | 0.7 | -2.9 |
Financial Ratios (x) and Margin Analysis (%)
| Ratio | FY2024 | FY2025 |
|---|---|---|
Net financial debt / EBITDA (x) | 2.4 | 2.4 |
Capex / Sales (%) | 5.5 | 5.9 |
FOCF conversion of EBITDA (%) | 8.3 | -38.2 |
EBITDA / financial result coverage (x) | 9.4 | 5.1 |
Revenue by Region
| Region | FY2024 | FY2025 |
|---|---|---|
APAC sales (EUR Mn) | 4,824 | 4,383 |
EMLA plus NA sales combined (EUR Mn) | 9,355 | 8,559 |
Group sales (EUR Mn) | 14,179 | 12,942 |
Valuation Snapshot
| Metric | Value |
|---|---|
IPO price (Oct 2015) | €24.00 (n/v) |
Takeover offer | €62.00 |
Squeeze-out compensation | €59.46 |
Last traded range (spring 2026) | ~€59.0–59.7 |
Dividend | Suspended since FY2022 |
Credit ratings | n/v (current) |
Analyst Conclusions
FY2026 guidance: EBITDA significantly above €740m; FOCF and ROCE significantly better.
Bull: H1 2026 EBITDA +64%; XRG capital/feedstock; STRONG savings.
Bear: Chinese overcapacity; European cost base; execution/incident risk.
Catalysts: squeeze-out registration; Q3 2026 results; CEO successor; MDI program milestones.
Analyst verdict. Covestro has passed from public equity story to strategic asset. Its trough in 2025 — sales €12.9bn, EBITDA €740m, net loss €644m — was severe, but H1 2026 shows a sharp rebound (EBITDA €669m, net income €120m) and guidance was raised. Under XRG, the company gains capital, feedstock and Gulf growth options, while independence diminishes. The thesis now hinges on cyclical normalisation in MDI/PC, delivery of €400m STRONG savings, and integration into XRG. Minority investors are effectively exiting at €59.46; for creditors and counterparties, credit quality is supported by ownership.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Since | Background |
|---|---|---|---|
Dr Markus Steilemann | CEO | CEO since 1 June 2018; Board member since 2015 | Joined Bayer 1999, Bayer MaterialScience 2004; head of Polycarbonates 2013–2015; will not extend contract beyond 31 May 2028 (announced 23 Feb 2026) |
Christian Baier | CFO (outgoing) | Oct 2023 – Sept 2026 | Previously Metro AG (2011–2023), CFO from 2016; negotiated ADNOC premium and €1.2bn capital injection |
Klaus Fröhlich | CFO (incoming) | From Oct 2026 | Group Chief Investment Officer of ADNOC since 2020; formerly Morgan Stanley head of Middle East investment banking; led Covestro IPO for Bayer in 2015 at Morgan Stanley |
Dr Thorsten Dreier | CTO & Labour Director | CTO since July 2023; Labour Director since Sept 2023; contract extended to 30 June 2031 | Responsible for Engineering, Process Technology, HSE & Reliability, Procurement |
Monique Buch | Chief Commercial Officer | Since Aug 2025 | Succeeded Sucheta Govil |
Major Shareholders
| Holder | Stake |
|---|---|
XRG P.J.S.C. (incl. ADNOC International Germany Holding AG) | ~95.1% (Mar 2026); 100% upon registration of squeeze-out |
Minority free float | ~4.9% pending squeeze-out effectiveness |
Insider ownership | Immaterial (n/v) |
Competitive Landscape
Competitors by Segment
| Segment | Key competitors |
|---|---|
MDI/TDI/polyols | Wanhua Chemical, BASF, Dow, Huntsman, Tosoh, Kumho Mitsui, Sadara (Dow/Aramco) |
Polycarbonate | SABIC, LG Chem, Lotte Chemical, Mitsubishi Chemical, Trinseo, Teijin, Chinese producers (Wanhua, etc.) |
Aliphatic isocyanates / coatings resins | Vencorex (partly acquired), Asahi Kasei, Evonik, Wanhua, BASF, Allnex, Arkema |
Peer Comparison FY2024
| Metric | Covestro | BASF | Dow | Huntsman |
|---|---|---|---|---|
Sales FY2024 (bn, local currency) | 14.2 EUR | 65.3 EUR | 43.0 USD | 6.0 USD |
EBITDA margin FY2024 (%) | 7.6 | n/v | n/v | n/v |



